American Journal of Kidney Diseases
Volume 54, Issue 6 , Pages 1034-1042 , December 2009

Subclinical Tubular Injury in HIV-Infected Individuals on Antiretroviral Therapy: A Cross-sectional Analysis

  • Andrew M. Hall, MD, MRCP

      Affiliations

    • Department of Cell and Developmental Biology, University College of London, London, UK
    • Centre for Nephrology, University College London, London, London, UK
    • Corresponding Author InformationAddress correspondence to Andrew M. Hall, MD, MRCP, Department of Cell and Developmental Biology, UCL, Gower St, London WC1E 6BT, UK
    • ,
  • Simon G. Edwards, MD, FRCP

      Affiliations

    • The Mortimer Market Centre, Camden Primary Care Trust, London, London, UK
    • ,
  • Marta Lapsley, MD, FRCPath

      Affiliations

    • South West Thames Institute for Renal Research, Epsom and St. Helier University Hospitals National Health Service Trust, Carshalton, London, UK
    • ,
  • John O. Connolly, MD, PhD, FRCP

      Affiliations

    • Centre for Nephrology, University College London, London, London, UK
    • ,
  • Kreesan Chetty, RGN

      Affiliations

    • The Mortimer Market Centre, Camden Primary Care Trust, London, London, UK
    • ,
  • Stephen O'Farrell, RGN

      Affiliations

    • The Mortimer Market Centre, Camden Primary Care Trust, London, London, UK
    • ,
  • Robert J. Unwin, MD, PhD, FRCP

      Affiliations

    • Centre for Nephrology, University College London, London, London, UK
    • ,
  • Ian G. Williams, MD, FRCP

      Affiliations

    • The Mortimer Market Centre, Camden Primary Care Trust, London, London, UK
    • Centre for Sexual Health and HIV Research, University College London, London, UK

Received 17 March 2009 ,Accepted 8 July 2009.

References 

  1. Wyatt CM, Klotman PE. Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection. Expert Opin Drug Saf. 2006;5:275–287
  2. Roling J, Schmid H, Fischereder M, et al. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis. 2006;42:1488–1495
  3. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002;16:1257–1263
  4. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients (Data from a double-blind randomized active-controlled multicentre study). Nephrol Dial Transplant. 2005;20:743–746
  5. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr. 2004;37:1489–1495
  6. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004;35:269–273
  7. Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med. 2004;117:282–284
  8. Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment—case report and review of literature. J Infect. 2005;51:E61–E65
  9. Quimby D, Brito MO. Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature. AIDS Read. 2005;15:357–364
  10. Brodehl J. Fanconi syndrome. In:  Edelmann CM editors. Pediatric Kidney Disease. Boston: Little Brown; 1992;p. 1841–1872
  11. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, et al. Drug-induced Fanconi's syndrome. Am J Kidney Dis. 2003;41:292–309
  12. Norden AG, Scheinman SJ, Schodt-Lanckman MM, et al. Tubular proteinuria defined by a study of Dent's (CLCN5 mutation) and other tubular diseases. Kidney Int. 2000;57:240–249
  13. Bernard AM, Moreau D, Lauwerys R. Comparison of retinol-binding protein and beta2-microglobulin determination in urine for the early detection of tubular proteinuria. Clin Chim Acta. 1982;126:1–7
  14. Price RG. The role of NAG (N-acetyl-beta-d-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol. 1992;38(suppl 1):S14–S19
  15. Ginsberg JM, Chang BS, Matarese RA, et al. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med. 1983;309:1543–1546
  16. Watanabe Y, Nunoi K, Maki Y, et al. Contribution of glycemic control to the levels of urinary N-acetyl-beta-d-glucosaminidase (NAG), total protein, beta2-microglobulin and serum NAG in type 1 (insulin-dependent) diabetes mellitus without macroalbuminuria. Clin Nephrol. 1987;28:227–231
  17. Lapsley M, Akers K, Norden AG. Sensitive assays for urinary retinol-binding protein and beta-2-glycoprotein-1 based on commercially available standards. Ann Clin Biochem. 1998;35(pt 1):115–119
  18. Levey AS, Bosch JP, Lewis JB, et al. Modification of Diet in Renal Disease Study Group A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461–470
  19. Kabanda A, Vandercam B, Bernard A, et al. Low molecular weight proteinuria in human immunodeficiency virus-infected patients. Am J Kidney Dis. 1996;27:803–808
  20. Papaleo A, Warszawski J, Salomon R, et al. Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir. Pediatr Infect Dis J. 2007;26:949–951
  21. Gatanaga H, Tachikawa N, Kikuchi Y, et al. Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2006;22:744–748
  22. Kinai E, Hanabusa H. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS. 2005;19:2031–2033
  23. Davey PG, Gosling P. Beta 2-microglobulin instability in pathological urine. Clin Chem. 1982;28:1330–1333
  24. Bernard AM, Lauwerys RR. Retinol binding protein in urine: a more practical index than urinary beta 2-microglobulin for the routine screening of renal tubular function. Clin Chem. 1981;27:1781–1782
  25. Izzedine H, Hulot JS, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis. 2006;194:1481–1491
  26. Norden AG, Lapsley M, Lee PJ, et al. Glomerular protein sieving and implications for renal failure in Fanconi syndrome. Kidney Int. 2001;60:1885–1892
  27. Kastner C, Pohl M, Sendeski M, et al. Effects of receptor-mediated endocytosis and tubular protein composition on volume retention in experimental glomerulonephritis. Am J Physiol Renal Physiol. 2009;296(4):F902–F911

 Originally published online as doi:10.1053/j.ajkd.2009.07.012 on September 24, 2009.

PII: S0272-6386(09)01029-4

doi: 10.1053/j.ajkd.2009.07.012

American Journal of Kidney Diseases
Volume 54, Issue 6 , Pages 1034-1042 , December 2009

Article Tools

* Image Usage & Resolution